US FDA advisers endorse Grail cancer test's benefits in key vote

A US FDA advisory panel unanimously supported the safety of Grail's Galleri multi-cancer blood test, with narrower endorsement on its effectiveness, recommending its benefits outweigh risks. A final FDA decision on national marketing authorization is expected soon.

This Wire brief sits within Fusion42's coverage of Medtech, and 10 sources have reported it between 21 Sep 2026 and 3 Oct 2026.